The battle against TB requires new, faster-acting medicines at affordable prices. The Lilly TB Drug Discovery Initiative, launched in June 2007, is a nonprofit public/private partnership focused on accelerating early-stage TB drug discovery. The initiative is run from a research facility in Seattle, Washington, and operates in partnership with the Infectious Disease Research Institute, MSD, and the National Institute of Allergy and Infectious Diseases, which is part of the U.S. National Institutes of Health. Bringing together specialists from around the world for the systematic exploration of vast, private molecular libraries, the initiative has a primary goal of filling the pipeline with new clinical candidates for future TB drug development.
Tackling MDR-TB has proven challenging. Less than one percent of estimated MDR-TB patients globally receive appropriate treatment. Over the past eight years, Lilly has learned a lot about the myriad obstacles blocking patient access to diagnosis and treatment. The strategy of transferring technology has proved especially timely, as we realize now that the need for medicines is much greater than anyone imagined when we first began.
Removing barriers will take a focused, coordinated effort by everyone committed to stamping out TB. Success depends on a sustained, joint commitment by governments, NGOs, and businesses to bring an end to this disease.
|Location||South Asia, North America, India, United States|